Indeed, intraperitoneal injection of NBD-peptide fused to an 8-Lysine CPP was able to inhibit NF-κB activation in response to lipopolysaccharide in macrophages and reduce NF-κB activation and disease pathology in an IL-10−/− mouse model of IBD [55]. This evidence concerns the gene NFKB1 and inflammatory bowel disease.